@article {7958,
	title = {Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience},
	journal = {Gynecologic Oncology},
	volume = {102},
	year = {2006},
	note = {Cited By :86Export Date: 21 February 2017},
	month = {2006},
	pages = {285 - 291},
	abstract = {Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC). Patients and methods.: A retrospective analysis was performed in patients with advanced stage of OCCC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 1/2/1987 and 31/10/2003. The outcome was compared to that of patients with sEOC treated according to the same protocols during the same study period. Results.: One hundred and five patients (35 stage III and IV OCCC, 70 stage III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for OCCC was 45\% (complete response 25\%) (95\% CI, 23.1\% to 68.5\%) and 81\% (complete response 46\%) (95\% CI, 67.4\% to 91.1\%) for sEOC. The overall response rate was significantly higher for sEOC (P~=~0.008). In the subgroup of stage III patients, the rate of complete responders was higher among sEOC patients (P~=~0.023). After a median follow-up of 61.1 months, median survival and time to tumor progression were not significantly different between the two groups (25.1 months [95\% CI 11.7 to 38.5 months] versus 49.1 months [95\% CI 36.5 to 61.6 months], P~=~0.141, 12.0 months [95\% CI 6.5 to 17.3 months] versus 18.0 months [95\% CI 14.7 to 21.6 months], P~=~0.384, respectively). Conclusion.: Patients with OCCC have significantly lower response to platinum-based first-line chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in significantly shorter survival. The current study outcomes are provocative and suggest that a new strategy for chemotherapy in OCCC should be adopted, possibly one that focuses on new agents without cross-resistance to platinum agents. {\textcopyright} 2006 Elsevier Inc. All rights reserved.},
	keywords = {Clear-cell epithelial ovarian cancer, Platinum-based chemotherapy, Response, Survival},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745901335\&doi=10.1016\%2fj.ygyno.2005.12.038\&partnerID=40\&md5=008e4ff8024530deac025ab6b7d29f99},
	author = {Pectasides, D. and Fountzilas, G. and Aravantinos, G. and Kalofonos, C. and Efstathiou, H. and Farmakis, D. and Skarlos, D. and N. Pavlidis and Economopoulos, T. and Dimopoulos, M.A.}
}
